Which DNA synthesis providers publicly state that they screen orders?

No jurisdiction reviewed in this dataset imposes a general legal duty on providers to screen synthetic nucleic acid orders. The strongest instrument identified is the United States OSTP/NSTC Framework for Nucleic Acid Synthesis Screening of April 2024, and it operates as a procurement condition rather than a direct obligation: federally funded purchasers must buy from providers that publicly self-attest to screening, so a provider faces no penalty for declining to attest — it simply becomes ineligible for that segment of the market. Of the 24 providers tracked, 0 operate under an identified binding requirement.

The IGSC is a voluntary industry association of commercial gene synthesis companies whose members commit to screening both order sequences and customers against a shared protocol. Membership is elective: a provider that never joins is not in violation of anything, and a member that relaxes its policy triggers no filing, notice, or penalty. That is why membership is a useful signal but not a guarantee, and why non-membership is not evidence of wrongdoing.

Because the dataset documents public disclosure, not company behavior. A provider can screen rigorously and never publish a page describing it. Recording “no” would assert a fact about internal practice that no external observer can verify from public sources. Every cell therefore reads “stated”, “not stated”, or “unverified”, and “not stated” means only that no public claim was found.

Of the 24 commercial DNA synthesis providers tracked, 7 publicly state that they screen order sequences and 11 publicly reference a US nucleic acid synthesis screening framework. 12 appear on the International Gene Synthesis Consortium member roster and 12 do not. 13 of 24 rows have been verified against the provider's own published materials so far; the remainder are marked unverified, which is an absence of a finding rather than a negative one. Each verified cell links to the provider's own source page and records the date it was read.

Because a designed genome is only a text file until a synthesis provider prints it. Turning a generated sequence into a physical organism requires a commercial supplier to accept the order, manufacture the strand, and ship it — making synthesis the one physical chokepoint in an otherwise all-software pipeline. Conventional screening also works by matching orders against databases of known hazardous sequences, an approach built on recognition that is structurally poorly suited to sequences a generative model produced precisely because they have never existed.

Monthly. An automated job re-fetches every provider's policy URL, hashes the extracted page text, and compares it against the stored hash from the previous run; any change opens a GitHub issue for human review. The dataset was last updated on 2026-08-07, and every row carries its own independent last-verified date.